MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Are These Medical Devices Safe? (Essure Permanent Birth Control)

Are These Medical Devices Safe? (Essure Permanent Birth Control)
FDA reports that it received over 900 adverse event reports between Essure's approval in 2002 and late 2013.

Essure Permanent Birth Control

The Essure system, now owned by Bayer after it acquired Conceptus in 2013, is intended to provide non-surgical permanent birth control. The Essure nickel-titanium alloy inserts, which look like small springs, are inserted hysteroscopically into the patient's fallopian tubes. After a three month wait, a confirmation test is used to determine that tissue ingrowth around the inserts has blocked the fallopian tubes, resulting in permanent birth control.

FDA reports that it received over 900 adverse event reports between Essure's approval in 2002 and late 2013. Common reported adverse events include pain, hemorrhage, headache, menstrual irregularities, device migration and breakage, among others. FDA reviewed the adverse events reported through late 2013, but said it found no new safety problems or evidence of a link between the Essure procedure and certain problems. 

In 2013, famous consumer advocate Erin Brockovich started campaigning against the Essure procedure. In February 2015, lawyers from the Law Office of Koch Parafinczuk & Wolf, P.A. sent a citizen petition to FDA making complaints against Essure. The lawyers, who wrote that they represent hundreds of women who received Essure, alleged that medical data was fraudulently fixed during the premarket approval process, and also alleged that conditions of the approval order and federal laws have been violated several times. The petitioners asked FDA to suspend Essure's approval. 

FDA responded to that citizen petition letter in March 2015, forwarding the claims on to the Office of Compliance within the Center for Devices and Radiological Health (CDRH). The Office of Compliance is tasked with reviewing the investigating the allegations and will take action if needed. 

Activists Say:

"...in many women, the devices migrate from the tubes, perforate organs, break into pieces, and/or corrode wreaking havoc on the female body.”

Marcus Susen and Justin Parafinczuk, attorneys at Koch Parafinczuk & Wolf, P.A. in a citizen petition letter to FDA

Industry Says:

"The Citizen's Petition regarding Essure was submitted to the FDA by a law firm that has filed several Essure product liability lawsuits naming Bayer as a defendant. The allegations made in the Citizen's Petition are similar to those stated in the lawsuits. Bayer stands behind the safety and efficacy of Essure and will aggressively defend itself in Court. FDA has closed the petition and forwarded it to the Office of Compliance. We are cooperating with the FDA, and we will respond to any questions that the agency may have related to the allegations."

—Bayer spokesperson, in an e-mailed statement for comment on a prior news story

FDA Says:

"To date, none of the above information the FDA reviewed has established a causal connection between Essure and certain reported problems, such as extreme fatigue, depression, and weight gain.”

FDA review of reported problems through late 2013

FDA Actions:

2013: Reviewed adverse event reports, results of an Essure post-approval study, and clinical literature, finding no new safety concerns, no increased incidence of complications, and no link between Essure and certain problems.

March 2015: Acknowledged citizen petition letter from Koch Parafinczuk & Wolf, P.A. and forwarded the complaint for investigation by CDRH's Office of Compliance.

[Image courtesy of Bayer HealthCare Pharmaceuticals Inc.]

Duodenoscopes da Vinci Surgical Robot
Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish